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Abstract
Background: Human Immunodeficiency Virus (HIV) infection predisposes to tuberculosis (TB). We described
incidence, risk factors and prognosis of TB in HIV-1 infected patients during pre (1995-1996), early (1997-1999), and
late Highly Active Antiretroviral Therapy (HAART) (2000-2007) periods.
Methods: We included patients from a population-based, multicenter, nationwide cohort. We calculated incidence
rates (IRs) and mortality rates (MRs). Cox’s regression analysis was used to estimate risk factors for TB infection with
HAART initiation included as time updated variable. Kaplan-Meier was used to estimate mortality after TB.
Results: Among 2,668 patients identified, 120 patients developed TB during the follow-up period. The overall IR
was 8.2 cases of TB/1,000 person-years of follow-up (PYR). IRs decreased during the pre-, early and late-HAART
periods (37.1/1000 PYR, 12.9/1000 PYR and 6.5/1000 PYR respectively). African and Asian origin, low CD4 cell count
and heterosexual and injection drug user route of HIV transmission were risk factors for TB and start of HAART
reduced the risk substantially. The overall MR in TB patients was 34.4 deaths per 1,000 PYR (95% Confidence
Interval: 22.0-54.0) and was highest in the first two years after the diagnosis of TB.
Conclusions: Incidence of TB still associated with conventional risk factors as country of birth, low CD4 count and
route of HIV infection while HAART reduces the risk substantially. The mortality in this patient population is high in
the first two years after TB diagnosis.
Background
The prognosis for Human Immunodeficiency Virus
(HIV) infected patients has changed dramatically after
the introduction of Highly Active Antiretroviral Ther-
apy (HAART) [1]. In spite of the effect of HAART,
tuberculosis (TB) is still one of the most frequently
acquired immune-deficiency syndrome (AIDS) defining
conditions worldwide [2]. Though effective, prevention
of TB in HIV positive by tuberculin skin testing and
targeted preventive treatments is of limited clinical
success [3,4]. In contrast, implementation of HAART
has been the best preventive measure and incidence
rates of TB co-infection have from Western World set-
tings been reported to decrease from the pre- to late-
HAART period. A European study reported incidence
rates before September 1995 of 0.8/100 person-years of
follow-up (PYR) decreasing to 0.3/100 PYR after
March 1997 [5]. The identification of risk factors for
development of TB is crucial for the design of strate-
gies to control the TB epidemic in the HIV-infected
population. Previously conducted studies in developed
countries all present significant associations between
both immigration from high-endemic TB regions and
low CD4 cell counts and increased risk of developing
active TB [2,6-8].
To our knowledge, no nationwide population-based
studies have been conducted on the incidence, risk fac-
tors and prognosis of HIV-associated TB during the
HAART era. The objective of the present study was to
determine the incidence of TB in the Danish HIV-
infected population during the pre-HAART (1995-
1996), early HAART (1997-1999), and late HAART
(2000-2007) periods and risk factors for developing
TB. We further aimed to describe mortality after TB
diagnosis.
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Methods
Study design
In the first part of the analysis, the study population was
the Danish HIV population (see below) diagnosed with
HIV in the period 1995-2007. In this population we esti-
mated incidence and risk factors for being diagnosed
with TB. In the second part of the study, the study
population was the HIV patients diagnosed with TB and
we determined mortality after diagnosis of TB.
Setting
Denmark had a population of 5.5 million as of 31
December 2007 [9], with an estimated HIV prevalence
of approximately 0.07% in the adult population [10].
Patients with HIV infection are treated in one of eight
specialized medical centres in the country, where the
patients are seen on an outpatient basis at intended
intervals of 12 to 16 weeks. Antiretroviral treatment is
provided free of charge to all HIV-infected residents of
Denmark. The national criteria for initiating HAART
have previously been described [11]. Directly observed
treatment (DOT) is not uniformly performed at the cen-
tres and treatment for latent tuberculosis is used infre-
quently in Denmark. TB diagnostic services are
centralised at the Mycobacteriology laboratory at Statens
Serum Institut in Copenhagen. This is the only labora-
tory in Denmark performing culture analyses for TB
ensuring that the diagnostic standard is uniform for all
participating centres.
Data sources
We used the unique 10-digit central person registration
number (CPR number), assigned to all Danish citizens
at birth or immigration, to track individuals in the fol-
lowing registries and to avoid multiple registrations.
The Danish HIV Cohort Study (DHCS) is a prospec-
tive, nationwide, population-based cohort study of all
HIV-infected patients treated in Danish HIV clinics
since 1 January 1995. Data are updated yearly and
includes demographics, date of HIV infection, AIDS-
defining events, date and reason of death, antiretroviral
treatment, CD4 cell counts and HIV-RNA measure-
ments. Study objects were identified from this registry
as were date of HIV diagnosis, TB diagnosis, demo-
graphics, CD4 cell counts, viral loads and antiretroviral
treatment.
The Danish Civil Registration System (DCRS) is a
national registry of all Danish residents established in
1967 that contains demographic data and vital status of
all Danish citizens. From this registry, we extracted date
of emi- and immigration and date of death.
The Danish National Hospital Registry (DNHR) was
initiated in 1977 and contains information on all
patients discharged from Danish non-psychiatric hospi-
tals including discharge diagnoses coded by the treating
physician according to the International Classification of
Diseases 10th revision (ICD-10) from 1994 and onwards.
From this registry, we extracted data on admissions
under all alcohol related diagnoses (F10.0 - F10.9 and
K70.2 - K70.3).
The Danish Registry of Causes of Death (DRCD) con-
tains information from all Danish death certificates
since 1943 and registration is currently complete
through 2006. Causes of death are coded according to
ICD-10 from 1994 through 2006. The causes of death
are registered by the treating physician on the death cer-
tificate as primary (immediate cause of death), secondary
or tertiary cause of death. From this registry we
extracted causes of death as recorded as the primary
cause of death [12] and classified the causes of death
into 3 categories: (1) related to TB, (2) not related to
TB, but related to HIV infection, or (3) not related to
HIV or TB.
Study population
We included all patients > 15 years diagnosed with
HIV-1 in Denmark in the period 1 January 1995 to 31
December 2007 and living in Denmark at the date of
HIV diagnosis.
Outcomes
In the first part of the study, outcome was time to first
diagnosis of TB (pulmonary as well as extra pulmonary).
Only TB cases diagnosed in the study period after HIV
diagnosis or within three months prior to HIV diagnosis
were included. A diagnosis of TB was defined as either
(1) definite, being the finding of acid fast bacteria in
sputum or body fluid/tissue by microscopy or PCR or
culture positive for Mycobacterium tuberculosis or (2)
presumptive, being clinical symptoms and/or paraclinical
findings suggestive of TB prompting anti-TB treatment
to be initiated and completed. In the second part of the
study outcome was time from TB diagnosis to death.
Statistics
Differences in characteristics between groups were eval-
uated by the c2test and Fisher’s exact test. Differences
were considered significant if P < 0.05.
In the first part of the study, time was calculated from
date of HIV diagnosis to date of TB diagnosis. Patients
were censored at date of last clinical follow-up, date of
death or 31 December 2007 which ever came first. Inci-
dence rates (IRs) for TB diagnosis and 95% confidence
intervals (95% CI) were calculated for the periods 1995-
1996, 1997-1999, 2000-2007 corresponding to pre, early
and late HAART periods. We also calculated IRs for TB
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for the following periods after HIV diagnosis: 0-1 year,
2-5 years and 6-10 years. Further, we used Cox regres-
sion model to calculate incidence rate ratios (IRRs) as
estimates of the impact of risk factors on incidence of
TB in the HIV infected population.
In the second part of the study, time was calculated
from date of TB diagnosis to date of death, emigration
or 31 December 2007, whichever came first. For patients
diagnosed with TB within three months prior to HIV
diagnosis, time was calculated from date of HIV
diagnosis.
We used Kaplan-Meier analysis to construct survival
curves.
The following covariates were included in the uni- and
multivariate models: gender, age at HIV diagnosis (≤ 40
years vs. > 40 years), country of birth/region (Denmark
vs. Europe vs. Africa vs., Asia vs. other), year of HIV
diagnosis (1995-1996 vs. 1997-1999 vs. 2000-2007), CD4
cell count at HIV diagnosis in the first part of the study
(≤ 200 cells/μL vs. > 200 cells/μL), CD4 cell count at
TB diagnosis in the second part of the study (≤ 200
cells/μL vs. > 200 cells/μL), viral load at HIV diagnosis
in the first part of the study and viral load at TB diagno-
sis in the second part of the study (≤ 5.0 log10 copies/
mL vs. > 5.0 log10 copies/mL), route of HIV transmis-
sion (heterosexual vs. homosexual vs. injection drug
user (IDU) vs. other) and alcohol abuse (previous inpati-
ent admission under alcohol-related diagnoses vs. no
previous inpatient admission under alcohol-related diag-
noses). We included date of first HAART initiation as a
time dependent variable.
The study was approved by the Danish Data Protec-
tion Agency. SPSS version 15.0 was used for data
analysis.
Results
From the Danish HIV Cohort Study we identified 2,668
patients diagnosed with HIV in the period 1995-2007
contributing with 14,711 person-years of follow up. The
characteristics of the study population are shown in
table 1. Due to HIV diagnosis prior to arrival in Den-
mark, 233 patients were excluded from the study of
whom 6 developed TB after immigration to Denmark.
In the study period, 120 patients met the criteria for a
diagnosis of TB. Overall the incidence in the period
1995-2007 was estimated to 8.2/1,000 person-years of
follow-up (PYR). Incidence rates decreased considerably
from the pre- to the early- and late-HAART periods
(table 2). The incidence of TB was highest in the first
year after HIV diagnosis and stabilized in the following
years (table 2).
The characteristics of patients diagnosed with TB are
shown in table 3. There were 120 patients (4.5%) diag-
nosed with TB among the 2,668 study participants, of
whom 69 (57.5%) had pulmonary TB, 38 (31.7%) had
extrapulmonary TB and 13 (10.8%) had both. At time of
the TB diagnosis 69 (67.0%) of the patients had a CD4
cell count less than 200 cells/μL. Only 28 (23.3%)
patients had started HAART prior to their TB diagnosis,
while 92 (76.7%) were diagnosed with TB before start of
HAART. Among the 92 patients, 29 (31.5%) were diag-
nosed with TB simultaneous with the HIV diagnosis, 15
(16.3%) were diagnosed with TB after the HIV diagnosis
Table 1 Characteristics of the HIV patients in the study
population
Characteristics N = 2,668
Emigrated during study period 90 (3%)
Died during study period 308 (12%)
Males 1,991 (75%)
Caucasians 1,944 (73%)
Country of birth
Denmark 1,843 (69%)
Europe 165 (6%)
Africa 412 (15%)
Asia 166 (6%)
Other 82 (3%)
Route of HIV transmission
Heterosexual 1,135 (43%)
Homosexual 1,090 (41%)
IDU 220 (8%)
Other 223 (8%)
Median age at HIV diagnosis, years (IQR*) 36.9 (30.3-45.2)
Median CD4 cell count at HIV diagnosis, cells/μL
(IQR*)**
290 (109.25-500.0)
Median HIV RNA at HIV diagnosis, log10 copies/mL
(IQR*)***
4.8 (4.2-5.4)
Exposed to HAART during study period 1,987 (75%)
Diagnosed with alcohol abuse 145 (5%)
* IQR: Inter Quartile Range.
** 532 patients had missing CD4 cell count at time of HIV diagnosis.
*** 673 patients has missing viral load at time of HIV diagnosis.
Table 2 Incidence of TB stratified by year of HIV
diagnosis
Period Observation
time PYR*
Number TB
diagnoses
Incidence rate
(TB/1000 PYR*)
95% CI**
1995-07 14710.5 120 8.2 6.8-9.8
1995-96 404.6 15 37.1 22.4-61.5
1997-99 1932.2 25 12.9 8.7-19.1
2000-07 12373.6 80 6.5 5.2-8.1
Incidence of TB stratified by years after
HIV-diagnosis
0-1 yr 2415.8 95 39.3 32.2-48.1
2-5 yrs 7175.8 17 2.4 1.5-3.8
6-10 yrs 4438.4 6 1.4 0.6-3.0
* PYR: person-years of follow-up.
** CI: Confidence Interval.
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and had a CD4 cell count of more than 200 cells/μL and
among the remaining 48 (52.2%) patients the median
time from HIV diagnosis to TB diagnosis was 10.5 days
(IQR; 6.0 - 30.5). We found no major differences in the
characteristics of patients diagnosed with TB in the peri-
ods 1995-1996, 1997-1999 and 2000-2007.
In univariate analysis the following factors were asso-
ciated with an increased risk of TB diagnosis: Male gender
(IRR: 2.1; 95% CI: 1.5-3.0; p-value < 0.001), age < 40 years
(IRR: 1.5; 95% CI: 1.0-2.3; p-value 0.036), country/region
of birth (Africa (IRR: 4.7; 95% CI: 3.1-7.0; p-value < 0.001)
and Asia (IRR: 5.9; 95% CI: 3.5-9.8; p-value < 0.001)) route
of HIV transmission (heterosexual (IRR: 3.9; 95% CI:
2.3-6.5; p-value < 0.001), IDU (IRR: 4.2; 95% CI: 2.1-8.4;
p-value < 0.001) and other (IRR: 4.6; 95% CI: 2.3-9.1;
p-value < 0.001)) and CD4 cell count ≤ 200 cells/μL at
HIV diagnosis (IRR: 3.8; 95% CI: 2.4-6.0; p-value < 0.001).
In the multivariate analysis only African (IRR: 4.3; 95% CI:
2.6-7.3; p-value < 0.001) and Asian (IRR: 5.7; 95% CI: 3.2-
10.1; p-value < 0.001) origin, route of HIV infection (het-
erosexual (IRR: 1.9; 95% CI: 1.0-3.5; p-value: 0.048), IDU
(IRR: 3.0; 95% CI: 1.5-6.2; p-value: 0.003) and other (IRR:
2.4; 95% CI: 1.2-4.9; p-value: 0.020)) and CD4 cell count
≤ 200 cells/μL at HIV diagnosis (IRR: 1.6; 95% CI: 1.1-2.2;
p-value: 0.005) preserved a statistically significant associa-
tion with increased risk of TB diagnosis. After start of
HAART the unadjusted and adjusted IRR for TB respec-
tively were 0.04 (95% CI: 0.03-0.07; p-value < 0.001) and
0.05 (95% CI: 0.03 - 0.08; p-value < 0.001) compared to
the time period before initiation of HAART (table 4).
Of the 120 TB patients, 19 died during the study per-
iod. Five deaths were recorded as related to TB, eight
deaths were recorded as related to HIV and six died of
other causes not related to HIV or TB or the cause of
death was unknown. 16 of the 19 patients died within
the first two years after HIV diagnosis. 9 (47%) of the 19
patients had a CD4 cell count < 200 cells/μl and 7 (37%)
had a CD4 cell count < 50 cells/μl at time of death. The
mortality was highest in the first two years after TB
diagnosis with a two year probability of survival of 85%
(95% CI; 78% - 92%), Figure 1. The five year probability
of survival was 81% (95% CI; 74% - 89%).
Table 3 Characteristics of the HIV infected patients diagnosed with TB
Year of TB diagnosis TB 1995-2007
N = 120
TB 1995-1996
N = 15
TB 1997-1999
N = 25
TB 2000-2007
N = 80
P value
Males 70 (58.3%) 11 (73.3%) 16 (64%) 43 (53.8%) 0.30
Median age, years (IQR*) 35.4 (30.8-42.5) 33.6 (31.2-38.5) 35.1 (29.6 - 45.5) 37.1 (30.8-42.9) 0.41
Birth country/region 0.80
Denmark 45 (37.5%) 5 (33.3%) 11 (44.0%) 29 (36.3%)
Europe 4 (3.3%) 1 (6.7%) 1 (4.0%) 2 (2.5%)
Africa 45 (37.5%) 7 (46.7%) 10 (40.0%) 28 (35.0%)
Asia 22 (18.3%) 2 (13.3%) 2 (8.0%) 18 (22.5%)
Other 4 (3.3%) 0 (0.0%) 1 (4.0%) 3 (3.8%)
Transmission of HIV 0.96
Homosexual 18 (15.0%) 3 (20.0%) 4 (16.0%) 11 (13.8%)
Heterosexual 72 (60.0%) 9 (60.0%) 16 (64.0%) 47 (58.8%)
IDU 15 (12.5%) 2 (13.3%) 2 (8.0%) 11 (13.8%)
Other 15 (12.5%) 1 (6.7%) 3 (12.0%) 11 (13.8%)
Diagnosis of alcohol abuse 13 (10.8%) 1 (6.7%) 2 (8.0%) 10 (12.5%) 0.38
Median HIV RNA at time of TB diagnosis, log10 copies/mL (IQR*)** 4.9 (3.6-5.9) 3.0 (2.7-3.9) 4.9 (4.2-5.9) 4.9 (3.6-5.9) 0.87
Median CD4cell count at time of TB diagnosis, cells/μL (IQR*)*** 120 (50-280) 150 (8-175) 110 (42-295) 120 (60 - 362) 0.94
CD4 cell count < = 200 cells/μL at time of TB diagnosis*** 69 (67.0%) 9 (81.8%) 14 (66.7%) 46 (64.8%) 0.54
Caucasians 43 (35.8%) 5 (33.3%) 11 (44.0%) 27 (33.8%) 0.67
HAART started before TB diagnosis 28 (23.3%) 1 (6.7%) 5 (20.0%) 22 (27.5%) 0.20
HAART during study period 104 (86.7%) 12 (80%) 23 (92.0%) 69 (86.3%) 0.55
Emigrated during study period 7 (5.8%) 1 (6.7%) 1 (4%) 5 (6.3%) 0.91
Dead during study period 19 (15.8%) 3 (20.0%) 6 (24.0%) 10 (12.5%) 0.35
Death within 2 yrs after HIV diagnosis 17 (14.2%) 3 (20.0%) 6 (24.0%) 8 (10.0%) 0.17
Median time from HIV to TB, months (IQR*) 0.6 (< 0.1-7.2) 0.6 (0.1-2.9) 0.4 (< 0.1 - 2.6) 0.8 (< 0.1-15.7) 0.30
Median time from TB to death, months (IQR*) 12.6 (0.6-17.8) 13.6 (0.0-58.8) 10.8 (0.5-41.6) 11.8 (1.7-17.7) 0.95
* IQR: Inter Quartile Range.
** 24 patients had missing viral load at time of TB diagnosis.
*** 17 patients had missing CD4 cell count at time of TB diagnosis.
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Discussion
In this nationwide, population-based cohort study, we
found that the incidence of TB in HIV-infected indivi-
duals peaks during the first year after HIV diagnosis and
decreased markedly after the introduction of HAART.
African and Asian origin, low CD4 cell count at HIV
diagnosis, lack of HAART and heterosexual and IDU
route of HIV transmission were risk factors for being
diagnosed with TB. To our knowledge this study is the
first to present a comprehensive, nationwide analysis of
incidence, risk factors of TB and prognosis of TB in
HIV infected individuals. Further, the study design
allowed long and nearly complete follow-up with the
inclusion of only patients diagnosed with HIV in the
study period after arrival to Denmark. Of importance
our study population was incident concerning HIV and
TB diagnosis.
The TB diagnosis was included in our analysis regard-
less of the patient being classified with presumptive or
definite TB. Some patients may therefore have been
misclassified leading to overestimation of the incidence.
However, due to the complexity of diagnosing TB
among HIV-positive individuals, presumptive TB, being
clinical symptoms and/or paraclinical findings suggestive
of TB, is by the majority considered sufficient for
further measures and initiation of TB treatment [5,13].
Unfortunately our study does not include data on
immune restitution inflammatory response (IRIS) which
has been reported in up to 7-36% in HAART-naive HIV
patients co-infected with TB [14].
Despite our large sample size and relatively long period
of observation, only 120 cases of TB were diagnosed,
which limits the strength of the multivariate analyses. To
obtain an incident cohort of HIV and TB we excluded
Table 4 Risk factors for being diagnosed with TB in HIV infected patients in Denmark
Risk factor Unadjusted analysis Adjusted analysis
Incidence rate ratio
(95% CI*)
p-value Incidence rate ratio
(95% CI*)
p-value
Male gender 2.1 (1.5-3.0) < 0.001 1.0 (0.6-1.5) 0.925
Age < 40 years 1.5 (1.0-2.3) 0.036 0.9 (0.6-1.4) 0.603
Year of HIV 1995-1996 1.0 1.0
Diagnosis 1997-1999 1.1 (0.6-1.9) 0.793 1.0 (0.6-1.6) 0.937
2000-2007 1.0 (0.6-1.7) 0.896 0.9 (0.5-1.6) 0.684
Country of birth Denmark 1.0 1.0
Europe 1.0 (0.4-2.9) 0.955 1.2 (0.4-3.4) 0.709
Africa 4.7 (3.1-7.0) < 0.001 4.3 (2.6-7.3) < 0.001
Asia 5.9 (3.5-9.8) < 0.001 5.7 (3.2-10.1) < 0.001
Other 2.0 (0.7-5.7) 0.173 1.3 (0.5-3.9) 0.586
Route of Homosexual 1.0 1.0
Transmission Heterosexual 3.9 (2.3-6.5) < 0.001 1.9 (1.0-3.5) 0.048
IDU 4.2 (2.1-8.4) < 0.001 3.0 (1.5-6.2) 0.003
Other 4.6 (2.3-9.1) < 0.001 2.4 (1.2-4.9) 0.020
Viral load at HIV diagnosis, log10 copies/mL** > 5.0 1.4 (0.8-2.2) 0.223 1.12 (0.8-1.6) 0.500
CD4 cell count at HIV diagnosis, cells/μL*** ≤ 200 3.8 (2.4-6.0) < 0.001 1.6 (1.1-2.2) 0.005
Diagnosed with alcohol abuse 1.3 (0.6-2.7) 0.447 1.9 (0.9-4.0) 0.106
Start of HAART (time-updated) 0.04 (0.03 - 0.07) < 0.001 0.05 (0.03-0.08) < 0.001
* CI: Confidence Interval.
** 673 patients has missing viral load at time of HIV diagnosis.
*** 532 patients had missing CD4 cell count at time of HIV diagnosis.
Figure 1 Probability of survival after diagnosis of tuberculosis.
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233 patients diagnosed with HIV before arrival in Den-
mark. Of these patients, 6 were found to have TB. With
regard to our findings on risk factors for TB, the omis-
sion of these patients may have altered our conclusions.
The small number of deaths did not allow us to identify
risk factors for death among the HIV patients with TB.
We chose to adjust for alcohol abuse using alcohol
related discharge diagnoses as registered in the Danish
Hospital Database, knowing that this is an incomplete
measure giving rise to unmeasured and residual
confounding.
We found a high incidence rate of TB among HIV
positive patients in Denmark of 8.2/1,000 PYR in the
period 1995-2007. The incidence of TB was remarkably
high the first year after being diagnosed with HIV - irre-
spective of the time period studied. Hereafter the inci-
dence rates declined steadily over time. Other studies
from regions with low TB incidence have found similar
incidence rates; Girardi et al. found an overall incidence
of 4.7 cases per 1,000 PYR in Europe and North Amer-
ica in a study conducted in the HAART era [15]. In
HIV patients from the United States, Markowitz et al.
found an incidence of 7 TB cases per 1,000 PYR [16], a
figure similar to that found in the EuroSIDA cohort,
which estimated an incidence of 8/1,000 PYR [5].
Interestingly, the incidence of TB declined significantly
with time after HIV-diagnosis, independently of the time
periods (pre-, early or late- HAART). Within the first
year of HIV-diagnosis we found an incidence of 39.9 TB
cases per 1,000 PYFU, a number approaching that seen
in Ethiopia and South Africa. In South Africa, however,
the high incidence persists after 5 years, being 10-fold of
that found in our study five years after HIV-diagnosis,
probably due to high prevalence of latent TB infection
and advanced immune suppression in a population
where HAART is not widely implemented or by other
co-morbidity [17,18]. Likewise, in our study the decline
in incidence of TB with time after HIV diagnosis is
most likely attributed to immunological restitution due
to HAART. Initiation of HAART and immunological
restitution may “unmask” TB as a part of IRIS which
probably also partially explains the high incidence of TB
in the first year after HIV diagnosis. Besides this, TB is
the most frequent AIDS defining disease and in many
African countries more than half of the TB patients are
diagnosed with HIV when diagnosed with active TB.
This bias may also contribute to the extremely high
incidence rate of TB seen in connection with the HIV
diagnosis and explain the rapid decline after diagnosis.
Concerning risk of a TB diagnosis, observational stu-
dies conducted both in low- and high-income countries
have shown that the risk of TB has decreased 50-90%
under HAART, yet not approaching that in the general
population [2,18]. Our study supports this finding with
a more than 90% decreased risk of TB after initiation of
HAART. However, some subgroups still remain at a
higher risk of developing TB than others. Findings simi-
lar to ours have been established in Brazil where base-
line CD4 cell counts of ≤ 200 cells/μL and lack of
HAART treatment both were independently associated
with increased risk of TB [18]. In a study cohort from
the United States, IDU, heterosexual contact, CD4 cell
counts ≤ 100 cells/μL and lack of antiretroviral therapy
were important risk factors for TB [16]. Not surprisingly
patients from high TB burden countries are at greater
risk of TB than others due to reactivation of latent TB
[8]. This may explain the finding of a higher risk of TB
among heterosexually HIV infected as this is the most
likely route of HIV transmission for the majority of Afri-
can and Asian immigrants [19,20].
The mortality was increased in the first two years after
the TB diagnosis, presumably due to a high degree of
immunodeficiency among the TB patients. The prog-
nosis was good after the first two years. The five year
probability of survival was comparable to that of other
studies [17,18,21].
Conclusions
We conclude that although the risk of TB has decreased
after the introduction of HAART it is still high and sub-
stantially higher in the first year after HIV diagnosis and
associated with African and Asian origin, low CD4
count and non-homosexual route of HIV infection. The
mortality is high in this patient population in the first 2
years after TB diagnosis.
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